Prevascar (INN: Ilodecakin) is a therapeutic formulation of human recombinant Interleukin 10. Prevascar is targeted at the potential market of prophylactic improvement of scar appearance in the skin, its mechanism of action is different to, and distinct from, that of Juvista. Prevascar is an important modulator of the inflammatory response.
Renovo has previously reported statistically significant Phase 2 efficacy data for Prevascar in the reduction of scarring in the skin. Following improvements in the manufacturing of Prevascar drug substance and product and the identification of patients who are predicted (on the basis of a Renovo non-drug experimental surgery study) to benefit particularly well from Prevascar's modulating effect on the wound inflammatory response, Renovo initiated a proof of concept clinical study in surgical skin incisions and excisions in African ancestral group volunteers. This trial should report final data in H1 2012. Renovo intends to sell the Prevascar programme to a suitable pharmaceutical / biotechnology company.